Global Opportunity Analysis in the Nasal Polyps Treatment Market to 2030: Compound Annual Growth of 5.6% is Forecast During 2021-2030 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Nasal Polyps Treatment Market by Type of Treatment, Route of Administration and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
The global nasal polyps treatment market was valued at $2,482.7 million in 2020 and is projected to reach $4,243.9 million by 2030 registering a CAGR of 5.60% from 2021 to 2030.
The main factors that drive growth of the nasal polyps treatment market include increase in prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP), along with rise in geriatric population, which are more vulnerable for development of chronic rhinosinusitis with nasal polyps.
In addition, rapid utilization of minimally-invasive surgeries by otorhinolaryngologic surgeons and huge product pipeline of nasal polyps treatment with growth in research activities further boost growth of the nasal polyps treatment market. However, high cost and complications associated with sinus surgeries such as excessive bleeding, cerebrospinal fluid leak, visual disturbances, postoperative scarring, and inflammation hinder growth of the market.
In addition, adverse reactions associated with steroid therapies such as weight gain, loss of bone mineral density, and cataract formation in eyes are expected to limit growth of the market. In contrast, technological improvements in nasal polyps treatment such as availability of key technologies such as nasal endoscopy and computerized tomography for nasal polyps treatment and diagnosis are expected to offer lucrative growth opportunities for players in the nasal polyps treatment market.
The global nasal polyps treatment market is segmented on the basis of type of treatment, route of administration, distribution channel, and region to provide a detailed assessment of the market. By type of treatment, it is bifurcated into corticosteroids, antibiotics, leukotriene inhibitors, and others. Others include antihistamines. By route of administration, it is segmented into oral, nasal, and others. Others include injectable and topical. On the basis of distribution channel, it is categorized into hospitals pharmacies, retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Report Benefits:
- The study provides an in-depth analysis of the nasal polyps treatment market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of nasal polyps treatment used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Market Segments:
By Type of Treatment
- Leukotriene Inhibitors
By Route of Administration
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Players Profiled
- AstraZeneca plc
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Intersect ENT Inc.
- Merck & Co Inc.
- Novartis International AG
- OptiNose US
- Regeneron Pharmaceuticals Inc.
- Sanofi S.A
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/e6z5c1
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900